Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications
Open Access
- 1 January 2003
- journal article
- Published by Sakun Publishing House in Journal of Carcinogenesis
- Vol. 2 (1) , 8
Abstract
J Carcinog, Official publication of Carcenogenesis PressKeywords
This publication has 27 references indexed in Scilit:
- The HER-2/neuOncogene in Tumors of the Gastrointestinal TractCancer Investigation, 2001
- Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma.2000
- Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressorsJournal of the American Academy of Dermatology, 2000
- Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.1997
- A comparative immunohistochemical study of mammary and extramammary Paget's disease and superficial spreading melanoma, with particular emphasis on melanocytic markersVirchows Archiv, 1996
- Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasisInternational Journal of Cancer, 1995
- Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.1994
- Novel Mutations of the KIT (Mast/Stem Cell Growth Factor Receptor) Proto-Oncogene in Human PiebaldismJournal of Investigative Dermatology, 1993
- GENE-EXPRESSION IN MELANOMA CELL-LINES AND CULTURED MELANOCYTES - CORRELATION BETWEEN LEVELS OF C-SRC-1, C-MYC AND P531990
- Signal transduction by receptors with tyrosine kinase activityCell, 1990